甲状腺微小乳头状癌的诊断及热消融治疗

doi:10.16352/j.issn.1001-6325.2024.12.1722

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (12): 1722-1726.doi: 10.16352/j.issn.1001-6325.2024.12.1722

甲状腺微小乳头状癌的诊断及热消融治疗

全英兰, 李宁^*

昆明理工大学附属安宁市第一人民医院超声医学科,云南昆明 650300

收稿日期:2024-02-04 修回日期:2024-05-11 出版日期:2024-12-05 发布日期:2024-11-26
通讯作者: ^*dtlining@sina.com
基金资助:
云南省周建桥专家工作站(202105AF150087);云南省春城青年拔尖人才专项(C202114008)

Diagnosis and thermal ablation of papillary thyroid microcarcinoma

QUAN Yinglan, LI Ning^*

Department of Ultrasound Medicine, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming 650300, China

Received:2024-02-04 Revised:2024-05-11 Online:2024-12-05 Published:2024-11-26
Contact: ^*dtlining@sina.com

摘要/Abstract

摘要： 甲状腺微小乳头状癌(PTMC)会发生颈部淋巴结转移,对PTMC患者早诊断、评估及治疗尤为重要。高频超声、超声造影、超声引导下的细针穿刺活检及基因检测已应用于PTMC的诊断,不断提高了PTMC 的检出率。近年来热消融术因其安全、高效、创伤小、术后恢复快等优点被应用于肿瘤的治疗领域,并取得不错得效果。

关键词: 甲状腺微小乳头状癌, 诊断, 微创治疗

Abstract: Papillary thyroid microcarcinoma may develop cervical lymph node metastasis, which is especially important for early diagnosis, evaluation and treatment of PTMC. High-frequency ultrasound, ultrasonography, ultrasound-guided fine-needle aspiration biopsy, and genetic testing have been applied to the diagnosis of PTMC, which has continuously improved the detection rate of PTMC. In recent years, thermal ablation has been applied to the treatment of tumors due to its advantages of safety, high efficiency, low trauma and fast post-operative recovery and has achieved good results.

Key words: papillary thyroid micro-carcinoma, diagnosis, minimally invasive treatment

中图分类号:

全英兰, 李宁. 甲状腺微小乳头状癌的诊断及热消融治疗[J]. 基础医学与临床, 2024, 44(12): 1722-1726.

QUAN Yinglan, LI Ning. Diagnosis and thermal ablation of papillary thyroid microcarcinoma[J]. Basic & Clinical Medicine, 2024, 44(12): 1722-1726.

参考文献

[1]Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71:209-249.
[2]Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020[J]. Lancet Diabetes Endocrinol,2022,10:264-272.
[3]Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014,74:2913-2921.
[4]Fagin JA,Wells SA Jr.Biologic and clinical perspectives on thyroid cancer[J].N Engl J Med,2016,375:2307.doi:10.1056/NEJMc1613118.
[5]Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2016,26:1-133.
[6]Ruan J, Xu X, Cai Y, et al. A practical CEUS thyroid reporting system for thyroid nodules[J]. Radiology,2022,305:149-159.
[7]Haddad RI, Bischoff L, Ball D, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2022,20:925-951.
[8]Xu H, Zhang Y, Wu H, et al. High diagnostic accuracy of epigenetic imprinting biomarkers in thyroid nodules[J]. J Clin Oncol,2023,41:1296-1306.
[9]Lu C, Li X, Chu X,et al. Clinical effects of microwave ablation in the treatment of low-risk papillary thyroid microcarcinomas and related histopathological changes[J].Front Endocrinol (Lausanne),2021,12:751213.doi:10.3389/fendo.2021.751213.
[10]Ma B, Wei W, Xu W, et al. Surgical confirmation of incomplete treatment for primary papillary thyroid carcinoma by percutaneous thermal ablation: a retrospective case review and literature review[J]. Thyroid, 2018,28:1134-1142.
[11]Baldwin CK, Natter MB, Patel KN,et al. Minimally invasive techniques for the management of thyroid nodules[J].Endocrinol Metab Clin North Am,2022,51:323-349.
[12]朱晨芳,陈江波,林庭伃,等.热消融技术治疗甲状腺良、恶性肿瘤的现状与展望[J].外科研究与新技术,2022,11:221-226.
[13]Ahmed M,Brace CL,Lee FT Jr,et al.Principles of and advances in percutaneous ablation[J].Radiology,2011,258:351-369.
[14]Yan L, Lan Y, Xiao J, et al. Long-term outcomes of radiofrequency ablation for unifocal low-risk papillary thyroid microcarcinoma: a large cohort study of 414 patients[J]. Eur Radiol, 2021,31:685-694.
[15]He H, Song Q, Lan Y, et al. Efficacy and safety of ultrasound-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma in patients aged 55 years or older: a retrospective study[J]. Int J Hyperthermia, 2021,38:604-610.
[16]Yan L, Zhang M, Song Q, et al. The efficacy and safety of radiofrequency ablation for bilateral papillary thyroid microcarcinoma[J].Front Endocrinol(Lausanne),2021,12:663636.doi:10.3389/fendo.2021.663636.
[17]Zaltieri M, Massaroni C, Cauti FM, et al. Techniques for temperature monitoring of myocardial tissue undergoing radiofrequency ablation treatments: an overview[J]. Sensors (Basel),2021,21:1453. doi: 10.3390/s21041453.
[18]Yong-Ping L, Juan Z, Li JW, et al.The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: a retrospective, single center study from China[J]. Front Endocrinol (Lausanne), 2022,13:946966.doi: 10.3389/fendo.2022.946966.
[19]Juan Z, Yongping L, Han X, et al. A 5-year follow-up study on the efficacy and safety of ultrasound-guided laser ablation in elderly patients with papillary thyroid microcarcinoma: a retrospective, single-center study from China[J]. Front Endocrinol (Lausanne), 2022,13:972589.doi:10.3389/fendo.2022.972589.
[20]Zhang L, Zhang GP, Zhan WW, et al. The feasibility and efficacy of ultrasound-guided percutaneous laser ablation for multifocal papillary thyroid microcarcinoma[J].Front Endocrinol(Lausanne),2022,13:921812.doi:10.3389/fendo.2022.921812.
[21]Kim C. Understanding the nuances of microwave ablation for more accurate post-treatment assessment[J]. Future Oncol,2018,14:1755-1764.
[22]Zhou W, Jiang S, Zhan W, et al. Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: preliminary results[J]. Eur Radiol, 2017,27:2934-2940.
[23]Teng DK, Li HQ, Sui GQ, et al. Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study[J]. Endocrine, 2019,64:109-117.
[24]Yu XY, Zhou HD, Wei Y, et al. Preliminary study of microwave ablation for multifocal papillary thyroid microcarcinoma in nonoperative candidates[J]. J Vasc Interv Radiol,2023,34:999-1006.

甲状腺微小乳头状癌的诊断及热消融治疗

Diagnosis and thermal ablation of papillary thyroid microcarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[2]	胡潮兴, 梁秋冬, 吴大鹏. 血清SAA4和SOCS1对脊柱结核与化脓性脊柱炎的早期鉴别价值[J]. 基础医学与临床, 2024, 44(7): 997-1001.
[3]	张睿, 谭妍, 马东来, 王蓉蓉, 张学. KIT杂合大片段缺失导致斑驳病一家系的临床表型[J]. 基础医学与临床, 2024, 44(7): 954-958.
[4]	王宇, 童安莉, 周玥, 张文倩, 崔云英, 景红丽, 李玉秀. ^99mTc-HYNIC-TOC显像和¹³¹I-MIBG显像在嗜铬细胞瘤和副神经节瘤中的诊断价值[J]. 基础医学与临床, 2024, 44(3): 374-378.
[5]	赵永忠, 薛懿, 李立群, 侯孟森, 杨晓军. 胆囊癌的早期影像学及循环标志物特征[J]. 基础医学与临床, 2024, 44(2): 265-269.
[6]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[7]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[8]	杜明月, 李学广, 左珊如, 陈紫淇, 周军华, 厉浩, 贺权源. 人工智能在癌诊断和治疗中的应用进展[J]. 基础医学与临床, 2022, 42(8): 1297-1301.
[9]	白小腾, 孙晓红, 赵翔宇, 李子坚. 检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展[J]. 基础医学与临床, 2022, 42(4): 661-666.
[10]	徐颖, 张宇. 纳米材料在医学检测与疾病诊断中的应用[J]. 基础医学与临床, 2022, 42(1): 33-40.
[11]	王铭, 赵辰阳, 韦瑶, 桂阳, 赵瑞娜, 王若蛟, 杨萌. 基于APP线上自主学习模式的关节超声诊断的精准教学探索[J]. 基础医学与临床, 2021, 41(9): 1371-1375.
[12]	杨庭楷, 文进, 纪志刚, 董德鑫, 叶子兴. 囊性嗜铬细胞瘤的诊断和治疗进展[J]. 基础医学与临床, 2021, 41(7): 1066-1070.
[13]	王立铨, 龙笑. 脂肪水肿的研究进展[J]. 基础医学与临床, 2021, 41(3): 438-441.
[14]	潘一鸣, 李耘, 马丽娜. 代谢相关生物学标志物在老年人衰弱中的研究进展[J]. 基础医学与临床, 2021, 41(3): 428-432.
[15]	王欣, 王铭, 赵峻, 王亚红, 吕珂, 朱庆莉, 李建初, 姜玉新, 杨萌. 北京协和医学院超声诊断教学需求的问卷调查及反馈分析[J]. 基础医学与临床, 2021, 41(3): 452-455.